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tion of amyloidoses may produce extracel-
lular deposits in multiple organs (Joachim 
et al., 1989). In this paper, Clos, Kayed, and 
Lasagna-Reeves present a novel perspective 
about the relation of dermis–epidermis–
brain and offer a review about amyloid 
deposits that are central to the strong “brain–
skin” connection. This connection starts as 
early as the sharing a joint embryological 
origin. Common multipotent embryonic 
progenitor stem cells from the ectoderm on 
the surface of the post-gastrulation embryo 
receive specific signaling from their envi-
ronment that instruct them to commit to 
a particular differentiation program which 
will give rise to the nervous system or skin 
epithelium (Quan and Hassan, 2005; Fuchs, 
2007). Clos, Kayed, and Lasagna-Reeves 
highlight common “brain–skin” patho-
physiological disorders such as the role of 
presenilin 1 (PS-1) for proteolytic process-
ing of the amyloid precursor protein (APP) 
which is altered in AD; alteration also found 
in skin cancers (Xia et al., 2001; Kang et al., 
2002). They also draw parallels between 
neurodegenerative disorders of Parkinson’s 
disease (Lewy bodies, α-synuclein, mela-
nin) and amyotrophic lateral sclerosis (ALS 
inclusion bodies) which share common fea-
tures with skin diseases (Hays et al., 2006). In 
addition, Clos, Kayed, and Lasagna-Reeves 
are describing transdermal route-of-entry as 
an elected administration route for potential 
medications to patients with neurodegen-
erative diseases such as Rivastigmine (AD 
and Parkinson), Rotigotine (Parkinson). 
A favorable coefficient of partition (physi-
ologically based pharmacokinetics, PBPK; 
Thrall et al., 2002) to the brain via the skin 
vector seems promising for potential drugs 
targeting the brain (Zhao et al., 2011). In 
PDAPP transgenic mice, the immunization 
with the 42-amino-acid form of the peptide 
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A brief history of amyloidosis goes back to 
autopsies of the seventeenth century report-
ing a waxing substance (Cordier, 2008). 
Later, in the middle of the nineteenth cen-
tury, Rudolph Virchow described an “amy-
loid” (starch, amulon, Greek, amylum, Latin) 
degeneration and infiltration of the lungs 
within alveoli and small vessels in a patient 
who presented with systemic amyloidosis 
(heart, lungs, liver, and kidneys; Cordier, 
2008). What amyloid-related diseases share 
is a common molecular ternary structure 
which involves abnormal aggregation of 
numerous widespread copies of the same 
protein into well-ordered filamentous 
β-sheet rich structures (Friedman, 2011) 
known as amyloid fibrils of 10–12 nm diam-
eters (Plante-Bordeneuve and Said, 2011). 
This abnormal accumulation of amyloid 
oligomers, protofibrils, or fibrils is con-
sidered to be one of the major contributor 
to neurodegeneration and the hallmark of 
Alzheimer’s (AD) and Parkinson’s diseases 
(Arora et al., 2004). A primary cause under-
lying these accumulations is the folding of 
polypeptide chains to specific three-dimen-
sional proteins in abnormal ways (Selkoe, 
2003). The progressive misfolding of spe-
cific proteins into aggregation may lead to 
cell alteration or death. Aggregated forms 
share many characteristics. One of them is 
that amyloid deposits show specific optical 
behavior such as birefringence on binding 
dyes (Congo red). The systemic distribu-
(Aβ42) prevents the development of cere-
bral β-amyloid-plaque formation, neuritic 
dystrophy and astrogliosis (Schenk et al., 
1999); the transdermal route has also been 
successfully used without detrimental side 
effects such as T cell infiltration and cere-
bral microhemorrhage (Nikolic et al., 2007). 
Occurrence of the systemic   deposition of 
β-amyloid protein in multiple tissues such 
as skin or brain infers that the initial amy-
loid protein may be produced locally in all 
organs affected or may, as observed in other 
human amyloidoses, be derived from a com-
mon circulating precursor (Joachim et al., 
1989). Therefore the transdermal β-amyloid 
immunization also directly targeting skin 
β-amyloid deposits may further reduce a 
potential source for amyloid precursors to 
other organs such as the brain.
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